Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02632110 · ClinicalTrials.gov registry record · Phase 2
Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face
A Phase 2 study, sponsored by DUSA Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
NCT02632110 is a Phase 2 study that has completed, run by DUSA Pharmaceuticals. The registered enrollment target is 137 participants.
The verdict
NCT02632110, a Phase 2 study, has completed, sponsored by DUSA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the viability of microneedle lesion preparation (MN) to enhance treatment benefit when performed prior to ALA PDT to an actinic keratosis (AK) field on the face.
Interventions
- DRUG ALA
- DRUG Topical Solution Vehicle
- DEVICE IBL 10 mW
- PROCEDURE Microneedle lesion preparation
- DEVICE IBL 20 mW
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2016-03 |
| Est. Completion | 2016-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02632110
The ClinicalTrials.gov registry entry for NCT02632110 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DUSA Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which ALA is the first listed.
NCT02632110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02632110 about?
NCT02632110 is a clinical study titled "Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face". The purpose of this study is to determine the viability of microneedle lesion preparation (MN) to enhance treatment benefit when performed prior to ALA PDT to an actinic keratosis (AK) field on the face.
What is the current status of trial NCT02632110?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2016-03. Estimated completion is 2016-09-12.
What interventions are being tested in trial NCT02632110?
The interventions under investigation include: ALA (DRUG), Topical Solution Vehicle (DRUG), IBL 10 mW (DEVICE), Microneedle lesion preparation (PROCEDURE), IBL 20 mW (DEVICE).
Who is sponsoring clinical trial NCT02632110?
This trial is sponsored by DUSA Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.